Gubra A/S
CSE:GUBRA
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
114
728
|
| Price Target |
|
We'll email you a reminder when the closing price reaches DKK.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Gubra A/S
PP&E Gross
Gubra A/S
PP&E Gross Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Gross | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
Gubra A/S
CSE:GUBRA
|
PP&E Gross
kr63.5m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Chemometec A/S
CSE:CHEMM
|
PP&E Gross
kr92m
|
CAGR 3-Years
29%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
Gubra A/S
Glance View
Nestled in the scientific hub of Denmark, Gubra A/S has carved a niche for itself in the dynamic world of biotechnology. Since its inception in 2008, the company has anchored its reputation on its pioneering work in preclinical contract research. At its core, Gubra specializes in providing pivotal insights and support for pharmaceutical giants working on metabolic and fibrotic diseases. Through meticulous study and advanced technological frameworks, such as their proprietary imaging platforms and tailored animal models, Gubra delivers essential data that propels drug discovery forward. Their B2B model thrives on collaborating with major pharmaceutical firms, assisting them in navigating the complex maze of early-stage drug development. Beyond its contract research capabilities, Gubra has also ventured into developing its own proprietary pipeline of peptide-based drug candidates. This dual-strategy approach demonstrates their deft versatility—balancing service-based revenue streams with the potential high returns from successful drug development. While their focus remains predominantly on addressing metabolic ailments like diabetes and obesity, the company's exploration into fibrosis shows a forward-thinking attitude towards expanding their portfolio. By combining cutting-edge research with strategic alliances, Gubra continues to position itself as a vital player in biotech, capturing the synergies between scientific innovation and commercial application.
See Also
What is Gubra A/S's PP&E Gross?
PP&E Gross
63.5m
DKK
Based on the financial report for Dec 31, 2023, Gubra A/S's PP&E Gross amounts to 63.5m DKK.
What is Gubra A/S's PP&E Gross growth rate?
PP&E Gross CAGR 3Y
-6%
Over the last year, the PP&E Gross growth was 14%. The average annual PP&E Gross growth rates for Gubra A/S have been -6% over the past three years .
You don't have any saved screeners yet